The candidate drug, TAK-875, was in the global phase-III development stage. Development was discontinued due to potential side-effects. As the drug is based on a novel mechanism of action and was positioned as a major source of future revenue, the announcement will...
The lectin was developed in a long-term NEDO project. Japan has about 3 million patients affected by viral hepatitis. NEDO news release, December 26, 2013
The initial projects will focus on biomarker for amyotrophic lateral sclerosis (ALS), the molecular basis of neurodevelopmental disorders in schizophrenia and research on the molecular pathogenesis and neural abnormalities in old age depression JST news release,...
The group of Professor Toshinori KINOSHITA overexpressed plasma membrane H+-ATPase in guard cells thus promoting light-induced stomatal (pore) opening and enhancing plant growth. Model organism was Arabidopsis thaliana. JST news release, December 24, 2013
